You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

405 Results
Drug
Other Name(s): Rybrevant®
Dec 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Nov 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Funding:
Exceptional Access Program
    alectinib - Adjuvant treatment of ALK-positive non-small cell lung cancer, according to specific criteria
Nov 2025
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    anastrozole
Dec 2025
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    letrozole
Dec 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
New Drug Funding Program
    Raltitrexed - Metastatic Colorectal Small Bowel or Appendiceal Cancer
Dec 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Dec 2025
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    exemestane
Dec 2025
Guidelines and Advice
Status: Current
Version: 1
Updated
Nov 2025

Pages